{
    "guideline": {
        "id": "PA166104959",
        "name": "Annotation of DPWG Guideline for tramadol and CYP2D6",
        "source": "DPWG",
        "version": 36,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104959",
        "relatedChemicals": [
            {
                "id": "PA451735",
                "name": "tramadol",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA128",
                "name": "cytochrome P450 family 2 subfamily D member 6",
                "symbol": "CYP2D6"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166302868",
            "name": "Recommendation Annotation PA166302868",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104467,
                "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
            ],
            "lookupKey": {
                "CYP2D6": "2.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302877",
            "name": "Recommendation Annotation PA166302877",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104476,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302864",
            "name": "Recommendation Annotation PA166302864",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104463,
                "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
            ],
            "lookupKey": {
                "CYP2D6": "0.75"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302873",
            "name": "Recommendation Annotation PA166302873",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104472,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302869",
            "name": "Recommendation Annotation PA166302869",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104468,
                "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
            ],
            "lookupKey": {
                "CYP2D6": "2.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302878",
            "name": "Recommendation Annotation PA166302878",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104477,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302865",
            "name": "Recommendation Annotation PA166302865",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104464,
                "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
            ],
            "lookupKey": {
                "CYP2D6": "1.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302874",
            "name": "Recommendation Annotation PA166302874",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104473,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302861",
            "name": "Recommendation Annotation PA166302861",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104460,
                "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative.\nDo not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
            ],
            "lookupKey": {
                "CYP2D6": "0.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302870",
            "name": "Recommendation Annotation PA166302870",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104469,
                "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
            ],
            "lookupKey": {
                "CYP2D6": "2.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302862",
            "name": "Recommendation Annotation PA166302862",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104461,
                "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
            ],
            "lookupKey": {
                "CYP2D6": "0.25"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302866",
            "name": "Recommendation Annotation PA166302866",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104465,
                "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
            ],
            "lookupKey": {
                "CYP2D6": "1.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302875",
            "name": "Recommendation Annotation PA166302875",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104474,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302871",
            "name": "Recommendation Annotation PA166302871",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104470,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "3.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302867",
            "name": "Recommendation Annotation PA166302867",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104466,
                "html": "<p>The guideline does not provide a recommendation for tramadol in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tramadol."
            ],
            "lookupKey": {
                "CYP2D6": "1.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302876",
            "name": "Recommendation Annotation PA166302876",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104475,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302863",
            "name": "Recommendation Annotation PA166302863",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104462,
                "html": "<p>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.</p>\n<ol>\n<li>Be alert to a reduced effectiveness.</li>\n<li>In the case of inadequate effectiveness:</li>\n</ol>\n<ul>\n<li>a. Try a dose increase.</li>\n<li>b. If this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.</li>\n</ul>\n<ol start=\"3\">\n<li>If no alternative is selected: advise the patient to report inadequate analgesia.</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia."
            ],
            "lookupKey": {
                "CYP2D6": "0.5"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302872",
            "name": "Recommendation Annotation PA166302872",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451735",
                    "name": "tramadol",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104471,
                "html": "<p>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.</p>\n<ol>\n<li>Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.</li>\n<li>If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</li>\n</ol>\n"
            },
            "implications": [
                "The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects."
            ],
            "lookupKey": {
                "CYP2D6": "4.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        }
    ],
    "citations": [
        {
            "pmid": "34267337",
            "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).",
            "authors": [
                "Matic Maja",
                "Nijenhuis Marga",
                "Soree Bianca",
                "de Boer-Veger Nienke J",
                "Buunk Anne-Marie",
                "Houwink Elisa J F",
                "Mulder Hans",
                "Rongen Gerard A P J M",
                "Weide Jan van der",
                "Wilffert Bob",
                "Swen Jesse J",
                "Guchelaar Henk-Jan",
                "Deneer Vera H M",
                "van Schaik Ron H N"
            ],
            "journal": "European journal of human genetics : EJHG",
            "year": 2022
        },
        {
            "pmid": "21412232",
            "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
            "authors": [
                "Swen J J",
                "Nijenhuis M",
                "de Boer A",
                "Grandia L",
                "Maitland-van der Zee A H",
                "Mulder H",
                "Rongen G A P J M",
                "van Schaik R H N",
                "Schalekamp T",
                "Touw D J",
                "van der Weide J",
                "Wilffert B",
                "Deneer V H M",
                "Guchelaar H-J"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2011
        }
    ],
    "version": "2024-03-25-16-13"
}